Most Popular News Stories on OBR Daily
(ASCO) Apr 29, 2020 - This year the American Society of Clinical Oncology (ASCO) will deliver the latest cancer science to the global oncology community in a new virtual format. Advances in immunotherapies and targeted therapies for lung, colorectal, ovarian, and bladder cancers; improvements in access to cancer care, as well as the impact of COVID-19 on people with cancer are among the topics that will be highlighted in the ASCO20 Virtual Scientific Program’s official Press Program. The ASCO20 Virtual Scientific Program, to be held May 29-31, will provide an engaging lineup of scheduled and on-demand scientific content across a variety of approaches, disciplines, and specialties. The theme of this year’s meeting is Unite and Conquer: Accelerating Progress Together.
(BioSpace) May 13, 2020 - Shares of bluebird bio are down nearly 7% in premarket trading after the U.S. Food and Drug Administration (FDA) declined to review a Biologics License Application for a CAR-T treatment for multiple myeloma co-developed with Bristol Myers Squibb. This morning, the companies announced the regulatory agency issued a Refusal to File letter regarding the BLA for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pretreated relapsed and refractory multiple myeloma. The two companies submitted the BLA in March.
(Karyopharm) Apr 29, 2020 - Karyopharm Therapeutics Inc., an innovation-driven pharmaceutical company, today announced that its late-breaking abstract detailing results from the pivotal, Phase 3 BOSTON study has been selected for oral presentation at the upcoming American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program taking place May 29-31, 2020. The BOSTON study is evaluating once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy.
(OneOncology) May 6, 2020 - OneOncology, the national partnership of independent community oncologists, today announced that Jeff Patton, MD has been named Chief Executive Officer. Patton has been Acting CEO and President of Physician Services since February. "Dr Patton is a visionary leader with high integrity who understands community oncology and how practices can thrive in today's changing environment better than anyone else in the country," said David Chernow, Chairman of the Board, OneOncology. "Especially in the wake of the COVID-19 pandemic, Dr Patton's leadership, vision, and track record of success are exactly the necessary ingredients to continue OneOncology's momentum and help its partner practices grow."
(BioPharma Dive) May 14, 2020 - The stocks of dozens of cancer drug developers shifted in value Thursday as investors got the first glimpse at clinical trial data set to be presented later this month at the American Society of Clinical Oncology's annual meeting, a top event for the field. Allogene Therapeutics appeared a clear winner, with shares in the biotech rising by nearly 30% on early signs its "off-the-shelf" cancer cell therapy could be effective in treating lymphoma. The preliminary data seemed to also help Cellectis, which originated some of the technology used by Allogene and saw shares climb 15%.
(Reuters) May 6, 2020 - Bristol Myers Squibb said on Wednesday the U.S. drug regulator had extended the review of its experimental blood cancer therapy by three months after the drugmaker submitted additional information to the agency. The company said the information was considered a major amendment to its marketing application and it would work closely with the U.S. Food and Drug Administration as it reviews the therapy.
(ABC News/AP) Apr 28, 2020 - For the first time, a blood test has been shown to help detect many types of cancer in a study of thousands of women with no symptoms of the disease. The test is still experimental. Even its fans say it needs to be improved and that Tuesday’s results are not ideal. Yet they show what benefits and drawbacks might come from using these gene-based tests, called liquid biopsies, in routine care -- in this case, with PET scans to confirm or rule out suspected tumors.
(Roche) May 19, 2020 - Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the US. Approval based on the Phase III IMpower110 study showing Tecentriq demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy.
(BioPharma Dive) May 13, 2020 - Roche is betting a new type of cancer immunotherapy could help to improve on the benefit offered by the first generation of immune-boosting drugs. Preliminary study results unveiled for the first time Wednesday give some reason for optimism in the Swiss drugmaker's approach, although the data fall short of showing a clear advantage over existing drug combinations.
(Yahoo! Finance) May 11, 2020 - OneOncology, the national partnership of independent community oncologists announced four oncology practices in Queens and Manhattan have chosen to join New York Cancer and Blood Specialists (NYCBS). OneOncology helps partner practices expand their services along the continuum of cancer care from screening and diagnosis to clinical trials, therapies, survivorship, and end-of-life care.